lorazepam has been researched along with Cystic Fibrosis in 3 studies
Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.
Cystic Fibrosis: An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The plasma disposition of three model substrates (lorazepam, indocyanine green, and antipyrine) and the formation clearance of antipyrine metabolites (3-hydroxymethylantipyrine, norantipyrine, and 4-hydroxyantipyrine) were evaluated in 15 subjects with mild cystic fibrosis and in 15 healthy control subjects." | 3.69 | Hepatic drug clearance in patients with mild cystic fibrosis. ( Crom, WR; Evans, WE; Karlson, KH; Kearns, GL; Mallory, GB, 1996) |
| "To examine whether hepatic drug metabolism is altered in patients with cystic fibrosis (CF), we evaluated the pharmacokinetics of three model pharmacologic substrates (antipyrine, a marker of hepatic oxidative metabolism; lorazepam, a marker of hepatic glucuronosyltransferase activity; and indocyanine green (ICG), a marker of hepatic blood flow and biliary secretion) in 14 patients with CF (14." | 3.68 | Enhanced hepatic drug clearance in patients with cystic fibrosis. ( Crom, WR; Evans, WE; Kearns, GL; Mallory, GB, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lewis, D | 1 |
| Blow, A | 1 |
| Tye, J | 1 |
| Hew-Butler, T | 1 |
| Kearns, GL | 2 |
| Crom, WR | 2 |
| Karlson, KH | 1 |
| Mallory, GB | 2 |
| Evans, WE | 2 |
3 other studies available for lorazepam and Cystic Fibrosis
| Article | Year |
|---|---|
Considering exercise-associated hyponatraemia as a continuum.
Topics: Adult; Aftercare; Anticonvulsants; Antidiuretic Agents; Confusion; Cystic Fibrosis; Deamino Arginine | 2018 |
Hepatic drug clearance in patients with mild cystic fibrosis.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Bile; C | 1996 |
Enhanced hepatic drug clearance in patients with cystic fibrosis.
Topics: Adolescent; Adult; Antipyrine; Biotransformation; Cystic Fibrosis; Female; Humans; Indocyanine Green | 1990 |